Cell Line Quality Technologies

Publication
Article
BioPharm InternationalBioPharm International-10-15-2016
Volume 2016 eBook
Issue 2
Pages: s23-s25

BioPharm International spoke with Selexis CEO and Chairman Igor Fisch, PhD about the latest cell-line development advances.

Chinese hamster ovary (CHO) cells are a common and stable option for mammalian expression systems, but what are the other cell line options in upstream processing and how do they compare in quality and stability to CHO cells? And what are the best techniques for ensuring quality and stability in cell-line development?  BioPharm International spoke with Selexis CEO and Chairman Igor Fisch, PhD about the latest cell-line development advances and the analytical techniques companies can use to ensure quality and stability.

 

Download the BioPharm International

Bioprocessing Trends 2016 eBook

.

Articles in this issue
Cell-Line-Quality-Technologies.jpg
Cell Line Quality Technologies
Human-Performance.jpg
Investigation Effectiveness Drives Human Performance Excellence
Data-Integrity-Challenges.jpg
Data Integrity Challenges in Manufacturing
Evaluating-Technology-and-Innovation-in-Biopharmaceutical-Manufacturing.jpg
Evaluating Technology and Innovation in Biopharmaceutical Manufacturing
Seeking-Accelerated-Biosimilar-Characterization.jpg
Seeking Accelerated Biosimilar Characterization
Plant-Made-Pharmaceuticals—Accelerating-Drug-Development-Globally.jpg
Plant-Made Pharmaceuticals—Accelerating Drug Development Globally
Testing-the-Broth.jpg
Testing the Broth
Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Cytiva Expands Bioreactor Portfolio with Addition of 500-L and 2000-L Bioreactors, Which Will be Exhibited at INTERPHEX 2025

Feliza Mirasol
March 25th 2025
Article

The addition of the two larger-volume bioreactor sizes to Cytiva’s Xcellerex X-platform portfolio will allow scientists and researchers to scale up from 50 L to 2000 L to meet growing demand for clinical trials and regulatory approved products.

Podcast: Alternative Drug Delivery Methods for Biologics: Where Are We At?

Podcast: Alternative Drug Delivery Methods for Biologics: Where Are We At?

Feliza Mirasol
September 27th 2024
Podcast

This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs.

DCAT Week 2025: Sustainability in Medical Propellants

DCAT Week 2025: Sustainability in Medical Propellants

Patrick Lavery
March 24th 2025
Article

PharmTech Group chatted with Markus Laubscher of Orbia during DCAT Week 2025, covering the topics of sustainability, regulatory hurdles, next-generation innovation, and the DCAT Week experience.

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Felicity Thomas
May 25th 2023
Podcast

Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Curia Expands Sterile Fill/Finish Site in UK

Feliza Mirasol
March 20th 2025
Article

Curia plans to expand its sterile fill/finish capabilities at its Glasgow, UK, site and gives updates on an ongoing expansion at its Albuquerque, NM, site.

TOP NEWS on grunge world map | Image Credit: © Sean K - stock.adobe.com

SGD Pharma Details Latest Sustainability Investments at DCAT Week 2025

Patrick Lavery
March 19th 2025
Article

The company is highlighting its commitment to next-generation glass manufacturing in efforts to strengthen the pharmaceutical supply chain.

© 2025 MJH Life Sciences

All rights reserved.